Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity (Q36278045)

13 August 2017

1 reference

title

Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity (English)

1 reference

13 August 2017

Michael T Yin

1 reference

13 August 2017

Marshall J Glesby

series ordinal

1 reference

13 August 2017

publication date

1 October 2005

1 reference

Expert Review of Anti-infective Therapy

13 August 2017

published in

1 reference

13 August 2017

1 reference

13 August 2017

1 reference

13 August 2017

page(s)

727-738

1 reference

Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Weight loss and wasting in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Guidelines for using body composition measurement in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Safety aspects of pharmacological GH therapy in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Growth hormone therapy in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Growth hormone treatment and risk of solid tumours. A statement from the Drugs and Therapeutics Committee of the European Society for Paediatric Endocrinology (ESPE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Increased mortality associated with growth hormone treatment in critically ill adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Pathogenesis and consequences of HIV-associated wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Efficacy of selected treatments of HIV wasting: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

"Buffalo hump" in men with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Visceral Obesity in Men: Associations With Glucose Tolerance, Plasma Insulin, and Lipoprotein Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Evaluation of regional body fat distribution: comparison between W/H ratio and computed tomography in obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Metabolic and adipose risk factors for NIDDM and coronary disease in third-generation Japanese-American men and women with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Adult growth hormone replacement: current understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

HIV induces thymus depletion in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

HIV-1-induced thymocyte depletion is associated with indirect cytopathicity and infection of progenitor cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

The dynamics of CD4+ T-cell depletion in HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Guidelines for Optimizing Growth Hormone Replacement Therapy in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

Association of Cancer With AIDS-Related Immunosuppression in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.727

21 January 2018

Identifiers

DOI

10.1586/14787210.3.5.727

1 reference

13 August 2017

1 reference